期刊
EXPERT REVIEW OF VACCINES
卷 20, 期 2, 页码 199-214出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14760584.2021.1873135
关键词
Malaria; monoclonal antibodies; plasmodium falciparum; standard membrane feeding assay; structural vaccinology; transmission blocking vaccine; vaccine design; ookinete; gametocyte; gamete; zygote; fertilization; pfs230; pfs48/45; pfs47; pfs25; pfhap2
类别
资金
- Intramural Research Program of the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Transmission-blocking vaccines (TBVs) aim to neutralize the sexual stages of Plasmodium parasites, preventing disease spread; Leading TBV candidates include Pfs230, Pfs48/45, Pfs47, Pfs25, and PfHAP2; Research on monoclonal antibodies isolated directly from humans and animal models has provided new insights into TBV efficacy and development.
Introduction: The development of effective vaccines remains a major health priority to combat the global burden of malaria, a life-threatening disease caused by Plasmodium parasites. Transmission-blocking vaccines (TBVs) elicit antibodies that neutralize the sexual stages of the parasite in blood meals ingested by the Anopheles mosquito, interrupting parasite development in the vector host and preventing disease spread to other individuals. Areas covered: The P. falciparum gametocyte surface antigens Pfs230, Pfs48/45, and Pfs47, the parasite ookinete surface protein Pfs25, and the male gametocyte specific protein PfHAP2 are leading TBV candidates, some of which are in clinical development. The recent expansion of methodology to study monoclonal antibodies isolated directly from humans and animal models, coupled with effective measures for parasite neutralization, has provided unprecedented insight into TBV efficacy and development. Expert opinion: Available structural and functional data on antigen-monoclonal antibody (Ag-mAb) complexes, as well as epitope classification studies, have identified neutralizing epitopes that may aid vaccine development and improve protection. Here, we review the clinical prospects of TBV candidates, progress in the development of novel vaccine strategies for TBVs, and the impact of structural vaccinology in TBV design.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据